RecruitingNot Applicable

Introduction of ACI for Cartilage Repair

Switzerland218 participantsStarted 2017-09-01

Plain-language summary

This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.

Age range15 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age between 15 and 50.
✓. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2
✓. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months)
✓. Subjects who understand and sign the consent form for this study

Rate of implantation-associated complications: serious adverse events (SAEs) and serious adverse reactions (SARs)

Timeframe: Up to 12 months.

Change in tissue integrity into and around the treated aera

Timeframe: 3 months post-implantation

Absence of infection after implantation.

Timeframe: 6 weeks post-implantation

NCT IDNCT04296487

SponsorCentre Hospitalier Universitaire Vaudois

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-09

Robin MARTIN, MD